Innovation in
Drug Delivery
Using Energy Based Systems
At Focal Medical, we’re applying our sophisticated technology platforms to revolutionize the way drugs are delivered to improve patient healthcare outcomes. Our goal is to reduce side effects, maximize the potency of drug therapy and yield better outcomes for patients.
intro
Effective drug delivery is important: All too often, drugs, when delivered systemically, affect the whole body solely in order to reach and treat a single target organ. In addition, drug delivery through the whole system may result in only limited exposure of the target organ to the therapeutic agent. To address these shortcomings and improve the active, localized and targeted delivery of drugs, we are channeling electrical forces in our drug delivery technology.
With our approach, we believe drug therapy can deliver better health outcomes, minimizing side effects and improving efficacy. We designed our patented, innovative technology solution to deliver therapeutic agents over a range of drug molecule sizes, both charged and neutral directly to the site of the diseased tissue.
technology
New hope for pancreatic cancer therapy
Our first program pursues one of cancer’s most significant unmet medical need — locally advanced pancreatic adenocarcinoma that’s unremovable at diagnosis. We expect to initiate our first clinical trial in 2023. Our confidence in this program is based on strong preclinical results from studies conducted at University of North Carolina – Chapel Hill and the significant unmet medical need which pancreatic patients face.
Facts
By deploying an electric field at the delivery site, we actively deliver drugs precisely and specifically to the target tissue or organ.
Our targeted mode of drug delivery utilizes non-blood pathways to actively drive treatment through tissues and into cells thus enhancing drug concentration, viability and perfusion in the target organ.
When treatment is not required across the body, systemic therapy can cause unwanted toxicity. Our precision delivery can avoid these unwanted side effects.
Because of the ways they are delivered, drugs often can’t overcome barriers and resistance created by disease. The continuous electrical flow from our device actively pushes and pulls drugs through these obstacles and directly into target cells for therapeutic effect.
meet the team
Our veteran team bridges the gap between biotechnology and medical device manufacturing, with experience in both startups and established companies. Our technology emerged from the labs of a distinguished surgical oncologist and a renowned chemical engineer and entrepreneur at the University of North Carolina. In addition to Series A funding, we have secured several grants from the National Institutes of Health.
news & updates
RALEIGH, N.C. (November 1, 2022): Focal Medical, Inc. (formerly Advanced Chemotherapy Technologies, Inc.), a privately held,…
This investment is in addition to the previously announced Series A investment of $5.5 million…
The capital will be used to fund initial clinical development of the company’s ACT-IOP-003 local…
Raleigh, NC, June 30th, 2020 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company…
Raleigh, NC, March 20th, 2020 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company…
Raleigh, NC, August 30th, 2019 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company…
Raleigh, NC, August 22nd, 2019 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company…
Tony Voiers joined Advanced Chemotherapy Technologies as CEO after meeting with company co-founder Jen Jen…
Focal Medical, Inc.
111 James Jackson Ave. Suite 131
Cary, NC 27513
Focal Medical Copyright 2022 | Focal Medical is an equal opportunity employer
Terms of service – Privacy policy – Other policies